Evaluation of the effects of multifocal lenses on visual performance in patients affected by bilateral cataract and treated with phacoemulsification (cataract surgery)

ISRCTN ISRCTN20862627
DOI https://doi.org/10.1186/ISRCTN20862627
Secondary identifying numbers CS2/725
Submission date
11/05/2021
Registration date
17/05/2021
Last edited
12/09/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Cataracts are when the lens, a small transparent disc inside your eye, develops cloudy patches. Over time these patches usually become bigger causing blurry, misty vision and eventually blindness.
Cataract surgery involves replacing the cloudy lens inside your eye with an artificial one.
The purpose of this study is to evaluate the visual results and patients’ satisfaction of surgical treatment of phacoemulsification (cataract surgery) and implantation of the innovative intraocular multifocal lens (MFIOL) Oculentis LENTIS Mplus MF30 in patients with bilateral (in both eyes) cataract.

Who can participate?
Adult patients over 50 years old with cataract in both eyes

What does the study involve?
We recruit candidates for bilateral cataract extraction surgery. Each subject undergoes complete ophthalmologic evaluation in the 90 days before the procedure. Each patient receives a preoperative prophylactic treatment with moxifloxacin eye drops (5 mg/mL), one drop three times each day for three days before the surgical procedure. Afterwards, each patient undergoes bilateral cataract extraction surgery. Each eye is treated during a different session, one 30 days after the other.
Prof. R. Nuzzi and his team will perform all surgical procedures. After surgery, patients are kept under observation for a few hours and later discharged according to standard protocol. They are subsequently asked to show up to follow-up ophthalmologic visits after one day (t1), seven days (t2), one month (t3), three months (t4) and six months (t6).

What are the possible benefits and risks of participating?
Participants will have their cataract removed and may have their visual acuity improve. Thanks to the implantation of a multifocal intraocular lens, they may reduce their spectacle dependence in everyday activities at different visual distances, which could not be achieved with standard mono-focal intraocular lenses. All participants are exposed to the risk of ocular surgery, which, although rare, can be severe, such as retinal detachment, ocular internal hemorrhage and infection, or less serious like corneal and/or retinal edema. Multifocal intraocular lenses may produce adverse visual effects in some patients, such as halos, glares, double vision, etc.

Where is the study run from?
Department of Ophtalmology, A. O. U. Città della Salute e della Scienza di Torino, Turin, Italy.

When is the study starting and how long is it expected to run for?
September 2017 to September 2020

Who is funding the study?
University of Turin (Italy)

Who is the main contact?
Prof. Raffaele Nuzzi, prof.Nuzzi_Raffaele@hotmail.it

Contact information

Prof Raffaele Nuzzi
Public

University of Turin
Via Cherasco 23
Turin
10126
Italy

ORCiD logoORCID ID 0000-0002-9213-2718
Phone +39 (0)116332220
Email raffaele.nuzzi@unito.it

Study information

Study designSingle-center interventional prospective non-randomized
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact detail below to request a patient information sheet.
Scientific titleEvaluation of the effects of multifocal lenses on visual performance in patients affected by bilateral cataract and treated with phacoemulsification: future prospects of a surgical treatment more oriented to the real refractive needs of the patient
Study objectivesThe purpose of this study was to evaluate the visual results and patients’ satisfaction of surgical treatment of phacoemulsification and implantation of the innovative intraocular multifocal lens (MFIOL) Oculentis LENTIS Mplus MF30 in patients with bilateral cataract.
Ethics approval(s)Approved 30/05/2018, Ethics Committee of A. O. U. Città della Salute e della Scienza di Torino (University of Turin, Corso Bramante 88/90 – 10126 Torino - Italy; +39 (0)11633.4171; comitatoetico@cittadellasalute.to.it), ref: CS2/725
Health condition(s) or problem(s) studiedCataract surgery (phacoemulsification)
InterventionWe recruit candidates for bilateral cataract extraction surgery. Each subject will undergo complete ophthalmologic evaluation in the 90 days before the procedure (as part of a standard preoperative practice), with:
● collection of personal data and anamnesis
● slit lamp ocular examination of the anterior segment and fundus oculi
● ocular applanation tonometry with Goldman tonometer
● determination of refraction and UCVA (uncorrected visual acuity) and BCVA (best-corrected visual acuity) for both eyes at 4m, 60 cm and 33 cm with ETDRS and Jaeger tables
● keratometry with Javal’s ophtalmometer
● optical eye biometry (Topcon Aladdin®) and contact eye biometry (we observed no differences between these two procedures; p > 0.1)
● corneal surface topography with Topcon Aladdin®
● photopic and mesopic pupillometry with Topcon Aladdin®

Each patient will receive a preoperative prophylactic treatment with moxifloxacin eye drops (5 mg/mL), one drop three times each day for three days before the surgical procedure. Afterwards, each patient underwent bilateral cataract extraction surgery. Each eye will be treated during a different session, one 30 days after the other.
Prof. R. Nuzzi and his team will perform all surgical procedures, which consisted in:
● Preoperative application of local mydriatic agents (Mydriasert) 1 h before surgery.
● Preoperative application of local anesthetics (Benoxinate, 0.4%).
● Sterile field preparation and disinfection with povidone-iodine for 3 minutes.
● Corneal tunnel incision of 2,2 mm and paracentesis followed by introducing viscoelastic fluid (Viscoat and Visthesia) in the anterior chamber.
● Execution of continuous circular capsulorhexis.
● Nucleus hydrodissection.
● Cataract extraction with phacoemulsification technique.
● MFIOL LENTIS Mplus LS-313 MF30 implantation in the capsular bag.
● Removal of viscoelastic fluid in front of and behind the lens.
● Hydrosuture.
● Disinfection and medication.

Oculentis suggests that the Mplus Lens category performs the best if the MFIOL that provides the minimal myopic shift is selected for implantation. Nevertheless, after ocular biometry, we will choose the IOL that will provide the minimal hyperopic shift for all patients bilaterally.
After surgery, patients will be kept under observation for a few hours and later discharged according to standard protocol.

They are subsequently asked to show up to follow-up ophthalmologic visits after one day (t1), seven days (t2), one month (t3), three months (t4) and six months (t6). On all those occasions, we will perform slit-lamp eye examination, ocular tonometry, refraction determination, monocular UCVA and BCVA evaluation for each eye at 4 m, 60 cm and 33 cm with ETDRS tables and Jaeger tables. We will evaluate the binocular UCVA at 4 m, 60 cm and 33 cm in the last three visits. In the same time intervals of one month, three months and six months, we will also assess patients' satisfaction, personal spectacle independence, the incidence of adverse visual effects, the treatment effect on different daily activities with specific questionnaires.
Intervention typeProcedure/Surgery
Primary outcome measure1. Postoperative uncorrected and best-corrected visual acuity for far distances is assessed with LogMar and ETDRS charts for each eye at 1 day, 7 days, 1 month, 3 months and 6 months
2. Postoperative uncorrected and best-corrected visual acuity for intermediate distances (60 cm) is assessed using the Jeager eye chart for each eye at 1 day, 7 days, 1 month, 3 months and 6 months
3. Postoperative uncorrected and best-corrected visual acuity for near distances (33cm) is assessed using the Jaeger eye chart for each eye at 1 day, 7 days, 1 month, 3 months and 6 months
4. Postoperative binocular uncorrected visual acuity for far (4 m), intermediate (60 cm) and near (33 cm) distances at 1 month, 3 months and 6 months
Secondary outcome measures1. Rate of visual disturbances was assessed with specific questionnaires with scores from 0 (for absence of disturbances) to 5 (for maximal difficulty) at 1 month, 3 months and 6 months after sugery
2. Spectacle dependence rate at far, intermediate and near visual distances was assessed with specifict questionnaires with scores from 0 (total independence) to 5 (for maximal dependence) at 1 month, 3 months and 6 months after sugery
3. Global visual satisfaction was assessed with specifict questionnaires with scores from 0 (absolutely not satisfied) and 10 (fully satisfied) at 1 month, 3 months and 6 months after sugery
4. Difficulties in everyday activities was assessed with specifict questionnaires with scores from 0 (total ease) to 5 (maximal difficulty) at 1 month, 3 months and 6 months after sugery
Overall study start date01/09/2017
Completion date30/09/2020

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants20
Total final enrolment20
Key inclusion criteria1. Bilateral cataract
2. Age >50 years
3. Regular corneal astigmatism, <1.00 D
4. K angle ≤1 mm
Key exclusion criteria1. Patient with optical means opacities other from cataract
2. Age-related macular degeneration
3. Previous history of ocular surgery
4. Irregular corneal astigmatism
5. Amblyopia
6. Concurrent neurologic or neuromuscular diseases (cerebral ictus, myasthenia, etc.)
7. Uncontrolled open/close-angle glaucoma
8. Severe ocular complications related to diabetes (retinopathy, macular oedema, vitreal hemorrhage, etc.)
9. Patients with operative or postoperative complications
10. Patients with a pupil diameter of ≤ 5,2 mm in mesopic lighting conditions
Date of first enrolment30/05/2018
Date of final enrolment01/03/2020

Locations

Countries of recruitment

  • Italy

Study participating centre

Ophthalmology Department of A.O.U. Città Della Scienza e Della Salute di Torino
Via Cherasco 23
Turin
10126
Italy

Sponsor information

University of Turin
University/education

Department of Ophtalmology
Department of Surgical Sciences
Via Cherasco 23
10126 Turin (TO)
Italy
Turin
10126
Italy

Phone +39 (0)116336922
Email roberto.vitali@unito.it
Website http://en.unito.it/
ROR logo "ROR" https://ror.org/048tbm396

Funders

Funder type

University/education

Università degli Studi di Torino
Government organisation / Universities (academic only)
Alternative name(s)
University of Turin in Italy, University of Turin, Italy, Università di Torino, 都灵大学, University of Turin, UNITO
Location
Italy

Results and Publications

Intention to publish date30/07/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer reviewed journal.
IPD sharing planThe datasets generated during and/or analysed during the current study are intended to be available upon reasonable request forwarded to the Institute of Ophthalmology of University of Turin (prof.Nuzzi_Raffaele@hotmail.it).

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 30/08/2022 12/09/2022 Yes No

Editorial Notes

12/09/2022: Publication reference added.
17/05/2021: Trial's existence confirmed by Ethics Committee of A. O. U. Città della Salute e della Scienza di Torino.